STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on developing precision genetic medicines through base editing, has announced its upcoming participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York. Investors and interested parties can access the live webcast through Beam's website investor section at www.beamtx.com, where it will remain archived for 60 days after the presentation.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-1.04% News Effect

On the day this news was published, BEAM declined 1.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York.

The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contact:

Holly Manning
Beam Therapeutics
hmanning@beamtx.com


FAQ

When is Beam Therapeutics (BEAM) presenting at the 2025 RBC Capital Markets Healthcare Conference?

Beam Therapeutics will present at the RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York.

Where can I watch Beam Therapeutics' (BEAM) presentation at the RBC Healthcare Conference?

The presentation can be viewed via live webcast in the investor section of Beam Therapeutics' website at www.beamtx.com and will be archived for 60 days afterward.

What type of company is Beam Therapeutics (BEAM)?

Beam Therapeutics is a biotechnology company that develops precision genetic medicines through base editing technology.

How long will Beam Therapeutics' (BEAM) RBC Conference presentation be available online?

The presentation will be archived and available for 60 days following the live webcast on Beam Therapeutics' website.
Beam Therapeutics Inc.

NASDAQ:BEAM

BEAM Rankings

BEAM Latest News

BEAM Latest SEC Filings

BEAM Stock Data

2.79B
100.19M
1.19%
105.17%
25.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE